131 related articles for article (PubMed ID: 31914797)
1. Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia.
Perez-Calahorra S; Civeira F; Guallar-Castillón P; Pinto X; Banegas JR; Pedro-Botet J; Suarez-Tembra M; Mauri M; Soler C; Rodriguez-Artalejo F; Laclaustra M
Eur J Prev Cardiol; 2020 Oct; 27(15):1649-1660. PubMed ID: 31914797
[TBL] [Abstract][Full Text] [Related]
2. Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia.
Climent E; Pérez-Calahorra S; Marco-Benedí V; Plana N; Sánchez R; Ros E; Ascaso JF; Puzo J; Almagro F; Lahoz C; Civeira F; Pedro-Botet J
Sci Rep; 2017 Jul; 7(1):5596. PubMed ID: 28717233
[TBL] [Abstract][Full Text] [Related]
3. Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients.
Pérez-Calahorra S; Sánchez-Hernández RM; Plana N; Marco-Benedi V; Pedro-Botet J; Almagro F; Brea A; Ascaso JF; Lahoz C; Civeira F;
Am J Cardiol; 2017 Mar; 119(5):742-748. PubMed ID: 28081939
[TBL] [Abstract][Full Text] [Related]
4. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
[TBL] [Abstract][Full Text] [Related]
5. Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population.
Séguro F; Bongard V; Bérard E; Taraszkiewicz D; Ruidavets JB; Ferrières J
Arch Cardiovasc Dis; 2015 Oct; 108(10):511-8. PubMed ID: 26073227
[TBL] [Abstract][Full Text] [Related]
6. Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
Marco-Benedí V; Laclaustra M; Bea AM; Suarez-Tembra M; Plana N; Pinto X; Brea A; Sanchez-Hernandez RM; Civeira F
Atherosclerosis; 2021 Mar; 320():47-52. PubMed ID: 33529866
[TBL] [Abstract][Full Text] [Related]
7. Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.
Climent E; Marco-Benedí V; Benaiges D; Pintó X; Suárez-Tembra M; Plana N; Lafuente H; Ortega-Martínez de Victoria E; Brea-Hernando Á; Vila À; Civeira F; Pedro-Botet J
Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1594-1603. PubMed ID: 33744038
[TBL] [Abstract][Full Text] [Related]
8. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study.
European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration
Lancet; 2024 Jan; 403(10421):55-66. PubMed ID: 38101429
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country.
Chlebus K; Zdrojewski T; Gruchała M; Gałąska R; Pajkowski M; Kocejko MR; Chmara M; Pencina MJ
Am Heart J; 2019 Dec; 218():32-45. PubMed ID: 31706143
[TBL] [Abstract][Full Text] [Related]
10. Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes.
Climent E; Pérez-Calahorra S; Benaiges D; Pintó X; Suárez-Tembra M; Plana N; Sánchez-Hernández RM; Valdivielso P; Ascaso JF; Pedro-Botet J
Rev Esp Cardiol (Engl Ed); 2020 Sep; 73(9):718-724. PubMed ID: 31672559
[TBL] [Abstract][Full Text] [Related]
11. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).
Pérez de Isla L; Alonso R; Mata N; Saltijeral A; Muñiz O; Rubio-Marin P; Diaz-Diaz JL; Fuentes F; de Andrés R; Zambón D; Galiana J; Piedecausa M; Aguado R; Mosquera D; Vidal JI; Ruiz E; Manjón L; Mauri M; Padró T; Miramontes JP; Mata P;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2004-10. PubMed ID: 27444203
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
Rallidis LS; Triantafyllis AS; Tsirebolos G; Katsaras D; Rallidi M; Moutsatsou P; Lekakis J
Atherosclerosis; 2016 Jun; 249():17-21. PubMed ID: 27062405
[TBL] [Abstract][Full Text] [Related]
13. Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender.
Mattina A; Giammanco A; Giral P; Rosenbaum D; Carrié A; Cluzel P; Redheuil A; Bittar R; Béliard S; Noto D; Quartarone A; Averna M; Bruckert É; Gallo A
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1068-1076. PubMed ID: 31378630
[TBL] [Abstract][Full Text] [Related]
14. Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia.
Liu MM; Peng J; Guo YL; Wu NQ; Zhu CG; Gao Y; Dong Q; Li JJ
Eur J Prev Cardiol; 2022 Jan; 28(16):1807-1816. PubMed ID: 33778872
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
Pijlman AH; Huijgen R; Verhagen SN; Imholz BP; Liem AH; Kastelein JJ; Abbink EJ; Stalenhoef AF; Visseren FL
Atherosclerosis; 2010 Mar; 209(1):189-94. PubMed ID: 19818960
[TBL] [Abstract][Full Text] [Related]
16. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients.
Béliard S; Millier A; Carreau V; Carrié A; Moulin P; Fredenrich A; Farnier M; Luc G; Rosenbaum D; Toumi M; Bruckert E;
J Clin Lipidol; 2016; 10(5):1129-1136.e3. PubMed ID: 27678429
[TBL] [Abstract][Full Text] [Related]
17. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca M
Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
[TBL] [Abstract][Full Text] [Related]
18. Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
Shek A; Alieva R; Kurbanov R; Hoshimov S; Nizamov U; Abdullaeva G; Nagay A
Atherosclerosis; 2018 Oct; 277():524-529. PubMed ID: 30270094
[TBL] [Abstract][Full Text] [Related]
19. Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia.
Real JT; Chaves FJ; Martínez-Usó I; García-García AB; Ascaso JF; Carmena R
Eur Heart J; 2001 Mar; 22(6):465-71. PubMed ID: 11237541
[TBL] [Abstract][Full Text] [Related]
20. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
